Maxcyte will present the MaxCyte® STX™ Scalable Transfection System which enables rapid development and consistent production of modified cell lines and primary cells for use in HTS and HCS cell based assays for ion channels, GPCR’s, and other targets. The MaxCyte STX transfects primary cells, cell lines, and stem cells with single or multiple agents, resulting in high loading efficiency, cell viability, reproducibility, and consistency with comparable results for both large (1E10 cells in 20-30 minutes) and small (5E5 cells in seconds) scale.
Visit booth 471 for a demonstration and attend the poster presentation “Rapid Development of Cell Based Assays for Screening GPCRs, Ion Channels and Other target Molecules’, Tuesday, January 26th at 1:00-3.00PM (access to this room is through the Exhibit Hall)
Here we demonstrate application of the MaxCyte STX system for screening single and multi-subunit ion channels, GPCRs and other molecules in HEK 293 and CHO cells. In these experiments, the transfected cells exhibited robust and consistent assay performance when analyzed using automated electrophysiology, dye flux, and high content screening instruments commonly used for high throughput drug screening and drug discovery applications. The data also illustrate typical examples of assay development in which small numbers of cells are transfected with increasing amounts of plasmid DNA using static electroporation to identify an optimal DNA concentration that yields good viability and sensitive assay performance. After optimizing loading conditions at small scale, the transfection process can be scaled up using flow electroporation without altering transfection efficiency, viability or assay performance. MaxCyte STX users can eliminate the costly, time consuming and labor intensive process of stable cell line development by transiently transfecting target and/or reporter molecules into cell lines and physiologically relevant primary cells or stem cells.